Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ICML 2019 | AATT study final results: allo or auto transplant for consolidation in T-cell lymphoma?

Olivier Tournilhac • 19 Jul 2019
ICML 2019
Lymphoma Non-Hodgkin Lymphoma Peripheral T-Cell Lymphoma Rare Diseases T-Cell Lymphoma
AATT

Olivier Tournilhac, MD, PhD, Clermont-Ferrand University Hospital, Clermont-Ferrand, France, discusses the Autologous or Allogeneic Transplantation in T-cell lymphoma (AATT) study. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

Screen reader support enabled.

Olivier Tournilhac, MD, PhD, Clermont-Ferrand University Hospital, Clermont-Ferrand, France, discusses the Autologous or Allogeneic Transplantation in T-cell lymphoma (AATT) study. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Olivier Tournilhac

Long-term outcomes of alloSCT for T-cell prolymphocytic leukemia
2:07
Long-term outcomes of alloSCT for T-cell prolymphocytic leukemia
Olivier Tournilhac • 8 Dec 2024
The current outcomes of patients with T-cell lymphoma and the unmet needs that remain
1:27
The current outcomes of patients with T-cell lymphoma and the unmet needs that remain
Olivier Tournilhac • 8 Dec 2024
The TOTAL trial: brentuximab vedotin + gemcitabine in R/R peripheral T-cell lymphoma
4:49
The TOTAL trial: brentuximab vedotin + gemcitabine in R/R peripheral T-cell lymphoma
Olivier Tournilhac • 8 Dec 2020

Related Videos

Federated learning to train generative AI models for diagnosis & prognosis of hematological diseases
2:08
Federated learning to train generative AI models for diagnosis & prognosis of hematological diseases
Olivier Tournilhac • 7 Dec 2025
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Olivier Tournilhac • 6 Dec 2025
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
2:10
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
Olivier Tournilhac • 8 Dec 2025
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
2:42
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
Olivier Tournilhac • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals